Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of Rebamipide Enemas in Active Distal Ulcerative Colitis and Proctitis: A Prospective Study Report

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Rebamipide has a broad spectrum of pharmacological actions that include suppression of neutrophil functions and stimulation of mucosal epithelial cell regeneration by increasing the expression of epithelial growth factor (EGF) and the EGF receptor. Sixteen patients with active ulcerative colitis (UC; mild in 1 patient, moderate in 11, and severe in 4) were recruited. Enemas containing 150 mg rebamipide per dosing were administered during the daytime after passage of stool, twice a day for 4 weeks. UC disease activity index (UC-DAI), endoscopic activity index (EAI), and Floren's grading (FG) of mucosal biopsy specimens were measured at entry and at 4 weeks. Five of 16 patients did not complete the study, and therefore, final efficacy assessment was done on 11 patients who completed the 4 weeks of treatment. Improvements were observed in UC-DAI (P= 0.0049), EAI (P= 0.0043), and FG (P= 0.0084). There was no serious rebamipide-related side effect in any of the 16 patients. In conclusion, rebamipide topical therapy appears to be effective for the treatment of mildly to moderately active distal UC. Further controlled studies are warranted for this promising drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allison MC, Dhillon AP, Lewis WG, Pounder RE (eds): Inflammatory Bowel Disease. London, Mosby, 1998, pp 15–95

    Google Scholar 

  2. Babb RR: Corticosteroids in ulcerative colitis: A skeptical view. J Clin Gastroenterol 10:365–367, 1988

    CAS  PubMed  Google Scholar 

  3. Present DH: How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 6:48–57, 2000

    CAS  PubMed  Google Scholar 

  4. Hanai H, Watanabe F, Takeuchi K, Saniabadi A, Bjarnason I: Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled study. Clin Gastroenterol Hepatol 1:28–35, 2003

    Article  PubMed  Google Scholar 

  5. Shanahan F: Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 120:622–635, 2001

    Article  CAS  PubMed  Google Scholar 

  6. Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahashi D, Mukumoto M, Nishimura N, Yasue K, Matsijimoto K: Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 20:783–792, 2004

    Article  CAS  PubMed  Google Scholar 

  7. Treulove SC: Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: a report on a controlled therapeutic trial. Br Med J 2:1072–1077, 1958

    Google Scholar 

  8. Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, Miglioli M, Barbara L: Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 32:929–931, 1991

    CAS  PubMed  Google Scholar 

  9. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk ED, Borgen L: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1894–1898, 1987

    CAS  PubMed  Google Scholar 

  10. Bianchi Porro G, Ardizzone S, Petrillo M, Fasoli A, Molteni P, Imbesi V: Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: A randomized, double-blind study. Am J Gastroenterol 90:736–739, 1995

    Google Scholar 

  11. Hanauer SB (for the U.S. PENTASA Enema Study Group): Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of multicentered placebo-controlled trial. Inflamm Bowel Dis 4:79–83, 1998

    Google Scholar 

  12. Selby WS, Bennett MK, Jewell DP: Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas. Digestion 29:231–234, 1984

    Article  CAS  PubMed  Google Scholar 

  13. Ryder SD, Walker RJ, Jones H, Rhodes JM: Rectal bismuth subsalicylate as therapy for ulcerative colitis. Aliment Pharmacol Ther 4:333–338, 1990

    CAS  PubMed  Google Scholar 

  14. Pullan RD, Ganesh S, Mani V, Morris J, Evans BK, Williams GT, Rhodes J: Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut 34:676–679, 1993

    CAS  PubMed  Google Scholar 

  15. Bjorck S, Dahlstrom A, Ahlman H: Topical treatment of ulcerative colitis with lidocaine. Scand J Gastroenterol 24:1061–1072, 1989

    CAS  PubMed  Google Scholar 

  16. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR: A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 106:1429–1435, 1994

    CAS  PubMed  Google Scholar 

  17. Zea-Iriarte WL, Makiyama K, Goto S, Murase K, Urata Y, Sekine I, Hara K, Kondo T: Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene sulphonic acid-induced colitis rats. Scand J Gastroenterol 31:985–992, 1996

    CAS  PubMed  Google Scholar 

  18. Genta RM: The role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther 18 (Suppl 1):8–13, 2003

    Article  CAS  PubMed  Google Scholar 

  19. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A: Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 43 (Suppl 9):5S–13S, 1998

    CAS  PubMed  Google Scholar 

  20. Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL: Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: A novel therapeutic alternative. Am J Gastroenterol 95:1838–1839, 2000

    Article  CAS  PubMed  Google Scholar 

  21. Farup PG, Hinterleitner TA, Lukas M, Hebuterne X, Rachmilewitz D, Campieri M, Meier R, Keller R, Rathbone B, Oddsson E: Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 7:237–242, 2001

    CAS  PubMed  Google Scholar 

  22. Rachmilewitz D on behalf of an international study group: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J 298:82–86, 1989

    Article  CAS  Google Scholar 

  23. Floren C-H, Benoni C, Willen R: Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 22:459–462, 1987

    CAS  PubMed  Google Scholar 

  24. Matts SGF: The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med, New Ser XXX 120:393–407, 1961

    Google Scholar 

  25. Hanauer SB, Present DH: The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 3:81–92, 2003

    PubMed  Google Scholar 

  26. Kornbluth A, Marion JF, Salomon P, Janowitz HD: How effective is current medical therapy for severe ulcerative colitis and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol 20:280–284, 1995

    CAS  PubMed  Google Scholar 

  27. Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892–895, 1977

    CAS  PubMed  Google Scholar 

  28. Kleine A, Kluge S, Peskar BM: Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 38:1441–1449, 1993

    Article  CAS  PubMed  Google Scholar 

  29. Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K: Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer: Comparison with cimetidine. Dig Dis Sci 40:2469–2472, 1995

    Article  CAS  PubMed  Google Scholar 

  30. Bamba H, Ota S, Kato A, Miyatani H, Kawamoto C, Yoshida Y, Fujiwara K: Effect of rebamipide on prostaglandin receptors–mediated increase of inflammatory cytokine production by macrophages. Aliment Pharmacol Ther 18 (Suppl 1):113–118, 2003

    Article  CAS  PubMed  Google Scholar 

  31. Tarnawski A, Arakawa T, Kobayashi K: Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats. One mechanism for its ulcer healing action? Dig Dis Sci 43:90S–98S, 1998

    CAS  PubMed  Google Scholar 

  32. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M: Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci 43 (Suppl 9):160S–166S, 1998

    CAS  PubMed  Google Scholar 

  33. Shimada S, Inoue K, Kuramoto M, Suzuki S, Yamamoto K, Ogawa M: Preoperative administration of rebamipide significantly lowers body temperature and circulating interleukin-6 in gastric cancer patients after gastrectomy. Dig Surg 20:500–505, 2003

    Article  CAS  PubMed  Google Scholar 

  34. Aihara M, Azuma A, Takizawa H, Tsuchimoto D, Funakoshi Y, Shindo Y, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K: Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci 43 (Suppl 9):174S–180S, 1998

    CAS  PubMed  Google Scholar 

  35. Marshall JK, Irvine EJ: Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40:775–781, 1997

    Article  CAS  PubMed  Google Scholar 

  36. Cohen RD, Woseth DM, Thisted RA, Hanauer SB: A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95:1263–1276, 2000

    CAS  PubMed  Google Scholar 

  37. Sinha A, Nightingale JMD, West KP, Berlanga-Acosta J, Playford RJ: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349:350–357, 2003

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endoscopy, Nagasaki University Hospital of Medicine and Dentistry, Nagasaki, Japan

    K. Makiyama MD, PhD (Dr.)

  2. Department of General Medicine, Nagasaki University Hospital of Medicine and Dentistry, Nagasaki, Japan

    F. Takeshima MD, PhD

  3. Department of Hospital Pharmacy, Nagasaki University Hospital of Medicine and Dentistry, Nagasaki, Japan

    T. Hamamoto MSc

  4. Department of Endoscopy, Nagasaki University Hospital of Medicine and Dentistry, Sakamoto 1-chome 7-1, Nagasaki, 852-8501, Japan

    K. Makiyama MD, PhD (Dr.)

Authors
  1. K. Makiyama MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Takeshima MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Hamamoto MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Makiyama MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Makiyama, K., Takeshima, F. & Hamamoto, T. Efficacy of Rebamipide Enemas in Active Distal Ulcerative Colitis and Proctitis: A Prospective Study Report. Dig Dis Sci 50, 2323–2329 (2005). https://doi.org/10.1007/s10620-005-3055-1

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-005-3055-1

KeyWords

Search

Navigation